On November 18, SELLAS Life Sciences Group Inc. fell 9.14% Overnight, trading at $17.39 per share, with turnover of $19,500.
The move followed the company’s launch of a $150.0 million underwritten public offering of common stock, with underwriters receiving a 30-day option to purchase up to an additional $22.5 million of shares.
The financing announcement came immediately after the stock’s sharp rally driven by positive Phase 3 REGAL data for galinpepimut-S in acute myeloid leukemia. The company reported the study met its primary endpoint, with median overall survival of 24 months versus 14.7 months for the control arm and a 41% reduction in risk of death, while saying it plans to discuss an accelerated regulatory filing strategy with the FDA. The equity raise suggests SELLAS Life Sciences Group Inc. is moving quickly to fund regulatory and commercialization steps, but the expected share issuance weighed on near-term sentiment.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments